Leerink Partnrs Forecasts Lower Earnings for Climb Bio

Climb Bio, Inc. (NASDAQ:CLYM) – Stock analysts at Leerink Partnrs reduced their FY2025 EPS estimates for Climb Bio in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn ($0.66) per share for the year, down from their prior forecast of ($0.65). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Climb Bio’s FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($1.14) EPS and FY2028 earnings at ($1.77) EPS.

Climb Bio (NASDAQ:CLYM) last announced its earnings results on Tuesday, November 12th. The company reported ($0.13) earnings per share for the quarter.

Separately, Leerink Partners started coverage on Climb Bio in a report on Monday, December 2nd. They issued an “outperform” rating and a $10.00 target price for the company.

Climb Bio Price Performance

Shares of CLYM stock opened at $1.55 on Monday. Climb Bio has a 52 week low of $1.53 and a 52 week high of $11.55. The firm has a 50 day simple moving average of $2.11. The stock has a market cap of $104.20 million, a PE ratio of -0.73 and a beta of -0.24.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.